Member Info for tuscany1

That was my last 15k buy at 88.2p today..lets see what next week brings .

Still remarkably cheap in my book so I have an oversized position it has to be said .

GLA.

Https://www.linkedin.com/posts/nick-ingrassia-a125bb7b_for-anyone-with-an-interest-in-the-upstream-ugcPost-7467268697892724736-k8CQ/

Seascape /Ingrassia presenting there on the 17th June ..

Https://seekingalpha.com/article/4896094-puretech-health-plc-prtc-q4-2025-earnings-call-transcript

Useful Q/A at the end

Https://www.investorschronicle.co.uk/content/5e94127c-17df-415d-9507-bfd3a89678b7

Https://www.linkedin.com/company/seascape-energy/posts/?feedView=all

Most of the team there yesterday .We can't be far away from a decision/presentation on the block we were interested in ..

Isn't Celea the elephant in the room .

If they cant get Celea etc away after almost 18 months post the 2B results doesnt that rather spoil the Seaport story .?

Bloomberg comment on that and other IPO's atm...The filings come amid robust investor demand for biotech stocks, with the Nasdaq Biotechnology Index closing at a record high Friday after adding to a more than 50% gain over the past year.

Https://www.fiercebiotech.com/special-reports/introducing-fierce-biotechs-2025-fierce-15

And this is worth reading too .Seaport was one of Fierce biotechs best 15 ideas last year .

Https://www.investorschronicle.co.uk/content/613b5bd5-6059-4c06-ae0d-bf3ab25ba2a6#mshktavp

Analysts at Singer Capital Markets increased their target price to 273p (from 257p) at the same time. The brokerage highlighted that after backing out R&D spend on new products the market is valuing the “core business at just 2.9 times enterprise valuation to cash profit with a 16 per cent free cash flow yield.”

So, with the group hitting regulatory milestones ahead of the launch of its first wave of new vaccines, this looks an opportune juncture to exploit the cheap valuation of the shares before the vaccines hit the market. On a conservative basis, the shares warrant a valuation at least in line with net asset value after accounting for minority interests, suggesting at least 130p a share, and materially higher in the likely scenario that the vaccines business gains traction. Buy.

Https://www.fiercebiotech.com/biotech/seaport-prepares-ipo-voyage-fund-depression-drugs-journey-phase-3

Worth a read .

My pervasive feeling is that there's just not much point in Puretech being a separate vehicle any more .Best just liquidate the assets in the best way however long it takes and call it a day .All the great and gifted people who are working for Puretech will find jobs down the line ..zero doubt .So my rhetorical question.. Is the Hub and Spoke model fit for purpose any more or has it had its day .?

I meant stale bulls of course,

I'm sure I speak for many on here who very much value your contributions Golfnut .I am more an oil and gas man so very much welcome someone who seems to be much more attuned to the Biopharma sector .Time in the market rather than timing indeed .

I might say that given PRTc's recent history there must be many stale bills out there who might be inclined to sell at something close breakeven tomorrow.But I really think now with this announcement and Celea/Gallop to follow this quarter its much better to hang on and follow the "time in the market" option .

Https://business-news-today.com/why-seaports-u-s-ipo-filing-matters-now-for-neuropsychiatric-drug-development-and-biotech-capital-markets/

Interesting summary

Just put a dummy sell in online and I can get 76.5p for 100k .

Mm's clearly short of stock atm

I've been topping up this morning .

When you think about it we are in a materially stronger position than 2 months ago when prices were in the low 80's .

Https://www.fiercepharma.com/pharma/march-ma-surge-triggers-high-expectations-2026

So will the shorts close now I wonder ?.

We'll be visiting a quid this time next week at this rate ..

Market cap £277m at 114p ...or 370m$.

Cash end June 25 $320m .Suppose they've spent 30m$ since .

So now $290m cash.

EV therefore just 80m$.

Was just looking at Avacta here in the UK still working on Phase 1 results .

EV around 385m$.

Just bizzare.